Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27157474 | 0.83 | ABCC3 (0.34) | ABCB11SLCO1B1 | |
| SCHEMBL22806839 | 0.83 | SLCO1B1 (0.41) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL29067845 | 0.82 | ABCB11 (0.38) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL18302270 | 0.79 | KDM4C (0.42) | DGAT1USP30KDM4CNPC1RAB9A | |
| SCHEMBL30740368 | 0.78 | TGFBR1 (0.44) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL23671228 | 0.77 | ABCB11 (0.35) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL19728935 | 0.77 | ABCB11 (0.34) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL24982985 | 0.75 | SLCO1B1 (0.39) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL21157317 | 0.74 | KDM4C (0.33) | KDM4CNPC1RAB9A | |
| SCHEMBL19715601 | 0.74 | SLCO1B1 (0.36) | ABCB11SLCO1B1KDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-20 | — | — | US | disclosed |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-12-07 | — | — | US | disclosed |
| CN-112521368-B | Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists | 百时美施贵宝公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-RE49352-E1 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220324829-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220249443-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-08-11 | — | — | US | disclosed |
| EP-4011875-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3666771-A1 | LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3472148-B1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-20 | — | — | US | disclosed |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | CHENG PETER TAI WAH (US) | 2018-11-22 | — | — | US | disclosed |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 91/4885ABCB11 2022/4885SLCO1B1 1507/4885 |
| US-20220249443-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 91/4885ABCB11 2022/4885SLCO1B1 1507/4885 |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 83/4885ABCB11 1766/4885SLCO1B1 1395/4885 |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 91/4885ABCB11 2022/4885SLCO1B1 1507/4885 |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | DGAT1 83/4885ABCB11 1766/4885SLCO1B1 1395/4885 |
| US-20220324829-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 83/4885ABCB11 1766/4885SLCO1B1 1395/4885 |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 91/4885ABCB11 2022/4885SLCO1B1 1507/4885 |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | DGAT1 91/4885ABCB11 2022/4885SLCO1B1 1507/4885 |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 83/4885ABCB11 1766/4885SLCO1B1 1395/4885 |
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 91/4885ABCB11 2022/4885SLCO1B1 1507/4885 |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | DGAT1 83/4885ABCB11 1766/4885SLCO1B1 1395/4885 |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | LPAR3, LPAR1, LPAR2 | DGAT1 83/4885ABCB11 1766/4885SLCO1B1 1395/4885 |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | DGAT1 83/4885ABCB11 1766/4885SLCO1B1 1395/4885 |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | DGAT1 91/4885ABCB11 2022/4885SLCO1B1 1507/4885 |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | DGAT1 91/4885ABCB11 2022/4885SLCO1B1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.